Essential thrombocythemia (ET) is a chronic myeloproliferative disorder characterized by megakaryocyte hyperplasia and thrombocytosis. The JAK2 V617F mutation has been reported in a variable proportion of ET patients ranging from 23 to 57%. These percentages have been determined in the majority of studies using granulocytes as the nucleic acid source and depend on the sensitivity of the detection techniques applied, being direct sequencing and allele-specific (AS)-PCR the most frequently used (reviewed by Steensma et al. 1 ). Application of more sensitive techniques such as quantitative real time PCR in DNA from granulocytes has yielded even higher detection rates (75%) mainly in newly diagnosed ET patients. 2 Although ET is characterized by a predominant megakaryocytic-platelet lineage involvement, there is scarce information about the prevalence of JAK2 V617F mutation in platelets. We have described the presence of the V617F mutation in growth factor-independent megakaryocytic colonies and also in platelets from five out of six ET patients. 3 In a recent study, JAK2 V617F was reported in 24 out of 50 ET patients when platelets were analyzed by AS-RT-PCR and restriction fragment length polymorphism. 4 Comparison of JAK2 V617F mutational status by conventional AS-PCR in granulocytes and platelets from 10 ET patients showed no differences in the detection rate between the two populations studied. 5 More recently, quantification of the JAK2 V617F in platelets and granulocytes in 13 ET patients showed a higher allele percentage in platelets than in granulocytes in a study that examined the reciprocity between JAK2 mutational status and Mpl expression. 6 Our aim was to systematically apply quantitative AS-RT-PCR to evaluate and compare the prevalence of the JAK2 V617F mutation in granulocytes and platelets in a series of 75 ET patients from a single institution. ET patients were diagnosed according to the WHO criteria. At the time when JAK2 mutation was analyzed 24/75 patients were receiving platelet-lowering therapy 7ASA, 24/75 patients only received antiaggregants and 27/75 received no specific treatment. None of them was receiving interferon. Twenty milliliter of venous blood was collected in ethylenediaminetetraacetic acid and immediately processed. Platelet-rich plasma was obtained by centrifugation of anticoagulated whole blood at 194 g for 10 min. Granulocytes were isolated by Lymphoprep (1077 g/ml) density gradient, followed by dextran sedimentation. Total RNA was isolated from granulocytes or platelets using guanidinium thiocyanate method (Ultraspec; Biotecx Laboratories, Houston, TX, USA). cDNA was reverse transcribed from 1 mg of total RNA with Murine Moloney Leukemia Virus reverse transcriptase (Invitrogen, Life Technologies, CA, USA) according to standard procedures with random hexamers. JAK2 V617F mutation was analyzed in duplicate by real-time AS-RT-PCR with probes specific for the mutated and the wild-type form as described previously. 7 A ratio between the Ct JAK2V617F and Ct JAK2WT was calculated for each sample.
The JAK2 V617F mutation was detected in both granulocytes and platelets in 43 out of 75 ET patients (57%), and was negative in both cell populations in the remaining 32 patients. It is worth to mention that the JAK2 V617F mutation had not been detected in six of the 43 mutated cases by direct sequencing using granulocyte cDNA or conventional AS-PCR performed with granulocyte DNA (following the methodology described by Baxter et al. 8 ). Although no difference was observed in the overall detection rate, when comparing platelets and granulocytes in the JAK2 V617F-positive cases, the mean Ct(JAK2V617F)/Ct(JAK2 wildtype) ratio was significantly higher, 1.05770.067, for granulocytes than for platelets, 1.02170.042 (P ¼ 0.003) (Figure 1a) . These results show that higher C t values for the mutated form were obtained when granulocytes were analyzed and reflect that the amount of the mutated form of JAK2 is lower in granulocytes than in platelets. To ascertain whether this Letters to the Editor observation was specific of ET patients, platelets and granulocytes from 40 polycythemia vera (PV) patients and nine primary myelofibrosis (PMF) patients were also analyzed. No significant differences were seen between granulocyte and platelet C t ratios (0.92570.106 and 0.94270.072, respectively, P ¼ 0.396) in PV patients or in PMF patients (0.93970.102 for granulocytes and 0.95070.060 for platelets, P ¼ 0.787). Interestingly, in the 17 patients bearing a homozygous V617F JAK2 (14 PV and 3 PMF) a lower C t ratio was observed in granulocytes than in platelets (P ¼ 0.001).
To correlate the C t ratio with the percentage of JAK2 V617F allelic burden present in both populations, we obtained a standard curve by diluting granulocytes from homozygous PV patients in normal cells. The mean JAK2 V617F percentage present in the granulocytic fraction from the 43 mutated ET patients corresponded to a 9.877.2%, whereas the allelic burden was significantly higher when platelets were analyzed (13.075.6 %, P ¼ 0.017). As shown in Figure 1b , this higher allelic burden in platelets was observed in the majority of ET patients. On the contrary, in PV and PMF patients the JAK2 V617F allelic burden was higher in granulocytes than in platelets, although this difference did not reach statistical significance.
We also studied the correlation between the median JAK2 V617F allelic percentage present in the samples (granulocytes or platelets) from ET patients and the detection of a clonal population by means of X-chromosome inactivation pattern (XCIP) analyzing the HUMARA gene. Patients with a clonal XCIP pattern (n ¼ 7) had a significantly higher mutant percentage in platelets than polyclonal patients (n ¼ 13) (P ¼ 0.013). However, this correlation did not reach statistical significance (P ¼ 0.062) when granulocytes were analyzed.
Our observation of a higher JAK2 V617F allelic burden in platelets than in granulocytes in ET patients is in agreement with the hypothesis that in this disease the clone is more tightly lineage restricted to cells with megakaryocytic potential. 3 On the other hand, this difference was not observed in PV and PMF patients, which is consistent with the known higher involvement of the granulocytic lineage characteristic of these diseases.
When facing how these results might modify the choice of the cell population to be studied in the clinical diagnostic laboratory, two facts should be taken into account: first, for the moment it is not necessary to quantify the mutated population for diagnostic purposes, and second, that it is equally informative to perform JAK2 V617F determination in granulocytes or platelets as long as a sensitive technique is employed. In this regard, it is important to emphasize that six of the 43 cases detected by quantitative AS-RT-PCR in our study had not been detected previously by direct sequencing using granulocyte cDNA or conventional AS-PCR performed with granulocyte DNA. However, when using a highly sensitive technique such as quantitative AS-RT-PCR, the overall detection rate was the same and in none of all the patients studied, the mutation was detected in one cell population, but not in the other. In our experience, analysis of granulocyte cDNA is 10-fold more sensitive than analysis of granulocyte DNA by quantitative PCR (0.5 vs 5% homozygous JAK2 V617F cells). Moreover, this difference may also explain why at least two articles have described the detection of the mutation in platelet cDNA, but not in granulocyte (or whole blood) DNA. 6, 9 In conclusion, the percentage of clonal population detected in ET patients was significantly higher in platelets than in granulocytes by quantitative AS-RT-PCR, a difference not observed in PV or PMF. This fact is in concordance with the predominant involvement of the megakaryocytic-platelet lineage in this disease. However, and given that the overall detection rate was the same using granulocytes or platelets, we consider that in the clinical setting and for ordinary diagnostic purposes, granulocytes remain a suitable target cell population to determine the JAK2V617F mutational status in ET patients, as long as a sensitive technique is employed. 
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